AZD8233 reduced low-density lipoprotein cholesterol levels by 73% in patients with high-risk hypercholesterolemia in ETESIAN Phase IIb trial

AZD8233 reduced low-density lipoprotein cholesterol levels by 73% in patients with high-risk hypercholesterolemia in ETESIAN Phase IIb trial  Self-administered subcutaneous monthly dose  with a potential best-in-class efficacy profile  Positive results from the ETESIAN Phase IIb trial s...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Ferrieres ,Midi Pyrées ,France ,French , ,Astrazeneca ,American College Of Cardiology ,World Health Organization ,Ionis Pharmaceuticals ,Nasdaq ,Lipids Health Dis ,Executive Vice President ,American College ,Annual Scientific ,Rare Diseases ,Eastern Europe ,Health Organization ,Categorization Using New American College ,American Heart Association Guidelines ,Cholesterol Management ,Its Relation ,Alirocumab Treatment Following Acute Coronary ,